Travere Therapeutics announced positive results from its Phase 3 PROTECT Study of FILSPARI in IgA nephropathy, demonstrating long-term kidney function preservation and a clinically meaningful difference in estimated glomerular filtration rate (eGFR) compared to irbesartan.